Clinical trials: Onchocerciasis
Lymphatic Filariasis
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB…
- Trial name
- NCT02899936
- Testing
- 3 drug dose - IDA, 2 drug dose - DA
- Where
- 4 sites in Haiti, India and 2 more
- Volunteers
- 23,789 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis, Ascaris Lumbricoides Infection
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in…
- Conditions
- Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, Hookworm Infections
- Trial name
- EKAIO (NCT07145736)
- Testing
- Moxidectin, Ivermectin
- Where
- Angola
- Volunteers
- 52,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Onchocerciasis
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O.
- Trial name
- NCT03876262
- Testing
- Moxidectin, Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 323 people
- Sponsor
- Medicines Development for Global Health
Lymphatic Filariases, Onchocerciasis
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic filariasis is a neglected tropical disease earmarked for elimination as a public health problem by the year 2020. Since the year 2000, the Global Program for the Elimination of LF has together with endemic countries…
- Trial name
- NCT03131401
- Testing
- Diagnosis of lymphatic filariasis, Diagnosis of lymphatic Filariasis and onchocerciasis, DEC Patch
- Where
- Ghana
- Volunteers
- 3,736 people
- Sponsor
- Noguchi Memorial Institute for Medical Research
Ivermectin, Onchocerciasis
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
Many studies have reported an association between epilepsy, including Nodding Syndrome (NS), and onchocerciasis (river blindness).
- Conditions
- Ivermectin, Onchocerciasis, Epilepsy
- Trial name
- OAETREAT (NCT03052998)
- Testing
- Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 91 people
- Sponsor
- Robert Colebunders
Onchocerciasis
Safety and Efficacy of IDA for Onchocerciasis
This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and…
- Trial name
- DOLF IDA/Oncho (NCT04188301)
- Testing
- IVM w/ ALB, Single dose of IDA, Three daily doses of IDA
- Where
- Ghana
- Volunteers
- 154 people
- Sponsor
- Washington University School of Medicine
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health
Onchocercal Subcutaneous Nodule, Epilepsy
Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study
This is an exploratory case control study with the aim to compare the Onchocerca volvulus virome between persons with onchocerciasis-associated epilepsy (OAE) and persons with onchocerciasis but without epilepsy.
- Conditions
- Onchocercal Subcutaneous Nodule, Epilepsy, Virus
- Trial name
- NCT05868551
- Testing
- nodulectomy
- Where
- South Sudan
- Volunteers
- 40 people
- Sponsor
- Universiteit Antwerpen
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Filariasis, Helminthiasis
Host Response to Infection and Treatment in Filarial Diseases
This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment.
- Conditions
- Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis
- Trial name
- NCT00001230
- Testing
- Diethylcarbamazine
- Where
- United States
- Volunteers
- 425 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis, Epilepsy
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
For the first time using a prospective design, a study confirms the results of previous retrospective studies, which found that strengthening onchocerciasis elimination efforts decreases the incidence of epilepsy, including…
- Trial name
- OAEMaridi (NCT05750043)
- Testing
- bi-annual CDTI
- Where
- South Sudan
- Volunteers
- 17,000 people
- Sponsor
- Universiteit Antwerpen
Lymphatic Filariasis, Onchocerciasis
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- DOLF-LIBERIA (NCT01905436)
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
- Where
- Liberia
- Volunteers
- 21,862 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis, Onchocerciasis
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Approximately 4,000 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- NCT02032043
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin MDA
- Where
- Côte d’Ivoire
- Volunteers
- 14,457 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Onchocerciasis
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
- Trial name
- NCT00127504
- Testing
- Rifampin, Azithromycin
- Where
- Guatemala
- Volunteers
- 80 people
- Sponsor
- Centers for Disease Control and Prevention
Nodding Syndrome, Epilepsy
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Background: Childhood epilepsy disorders are particular frequent in the area around Mahenge, southern Tanzania and recent studies have described a novel type of epilepsy with repetitive head nodding episodes and often progressive…
- Conditions
- Nodding Syndrome, Epilepsy, Onchocerciasis, Cognitive Impairment
- Trial name
- NSEC (NCT03653975)
- Testing
- no intervention
- Where
- Tanzania
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Onchocerciasis, Epilepsy
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
Onchocerciasis is a neglected tropical disease associated with epilepsy, particularly in areas of high Onchocerciasis volvulus transmission.
- Trial name
- OAETanzania (NCT05749653)
- Testing
- Bi-annual CDTI
- Where
- Tanzania
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Onchocerciasis (River Blindness), Schistosomiasis
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
Neglected Tropical Diseases (NTDs) are among the most common groups of diseases affecting over one billion people globally and are disproportionately concentrated in remote, underserved, and marginalized communities.
- Conditions
- Onchocerciasis (River Blindness), Schistosomiasis, Soil Transmitted Helminth (STH) Infections, Lymphatic Filariasis
- Trial name
- MISSION (NCT07707817)
- Testing
- Modified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg
- Where
- Nigeria
- Volunteers
- 5,760 people, healthy volunteers welcome
- Sponsor
- Uwemedimo Friday Ekpo
Onchocerciasis
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
The purpose of this study is to measure the amount of moxidectin in subjects' blood and to measure safety. This study will enroll 36 children aged 4 to 11 years (>=12 kg) with or without Onchocerca volvulus (O volvulus)…
- Trial name
- NCT01035619
- Testing
- moxidectin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Onchocerciasis
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
The DOLF Ocular Changes after Ivermectin study will investigate the kinetics of O. volvulus microfilaria (Mf) in the eye following treatment with ivermectin.
- Trial name
- NCT03517462
- Testing
- Ivermectin 3Mg Tab
- Where
- Ghana
- Volunteers
- 231 people
- Sponsor
- Washington University School of Medicine